221 results on '"Takeshita, Takashi"'
Search Results
2. Addressing ESR1 Mutation: A Key Factor in Hormone Therapy Resistance in Breast Cancer
3. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
4. Addressing ESR1 Mutation: A Key Factor in Hormone Therapy Resistance in Breast Cancer
5. Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer
6. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
7. Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment
8. Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment
9. Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum
10. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
11. Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature
12. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
13. Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
14. High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment
15. Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction
16. Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor
17. dPCR Mutational Analyses in Cell-Free DNA: A Comparison with Tissues
18. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
19. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
20. A case of premenopausal breast cancer with symptomatic cerebellar metastasis successfully treated by systemic endocrine therapy alone: relationship to biological features
21. Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment
22. Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens
23. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
24. Factors involved in early lenvatinib dose reduction: a retrospective analysis
25. Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy
26. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment
27. Evaluation of a new combination product with novel medical device for pegfilgrastim administration
28. A 9-Gene-Based Molecular Prognostic Model Precisely Predicts Survival and Treatment Response in Breast Cancer Patients
29. WS8-3 - Incidence and clinical relevance of ESR1 mutations in estrogen receptor positive breast cancer patients
30. Effects of sequential and discrete rapid naming on reading in Japanese children with reading difficulty
31. Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report
32. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment
33. Clinical Implications of Occult Metastases and Isolated Tumor Cells in Sentinel and Non-Sentinel Lymph Nodes in Early Breast Cancer Patients: Serial Step Section Analysis with Long-Term Follow-Up
34. Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents
35. Evaluation of a novel medical device for pegfilgrastim administration.
36. The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer
37. Abstract 1607: Pro-cancerous immune profile in primary breast tumors affects the timing and type of breast cancer recurrence
38. Abstract OT2-02-07: Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)
39. Abstract P5-11-12: Clinical value ofESR1mutations from cell free DNA in ethynil estradiol treatment for metastatic breast cancer
40. Abstract P3-08-59: High expression microRNA-143 is associated with favorable tumor immune microenvironment and better survival of ER positive breast cancer patients
41. HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence
42. High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
43. Additional file 1: of Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
44. Abstract 5252: High expression of PLK1, polo-like kinase 1, is significantly associated with DNA repair deficiency, inactivated TP53, and worse prognosis in breast cancer
45. Procancerous immune cells in primary tumor is associated with breast cancer recurrence.
46. The ubiquitin E3 ligase activity of BRCA1 and its biological functions
47. Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling
48. APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer
49. Abstract 1583: Clinical significance ofPIK3CA,AKT1, andESR1mutation in plasma cell-free DNA from estrogen receptor-positive breast cancer patients
50. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.